Related Experiment Video
Updated: Feb 15, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
Review: Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy
1Department of Genetics and Cytogenetics, AP-HP, Institut du Cerveau et de la Moelle Epinière (ICM) - Hôpital Pitié-Salpêtrière, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Inserm U1127, CNRS UMR 7225, Paris, France.
Abstract:
Over the last decade, there has been increasing evidence that hyperactivation of the mechanistic target of rapamycin (mTOR) pathway is a hallmark of malformations of cortical development such as focal cortical dysplasia (FCD) or hemimegalencephaly. The mTOR pathway governs protein and lipid synthesis, cell growth and proliferation as well as metabolism and autophagy. The molecular genetic aetiology of mTOR hyperactivation has only been recently clarified. This article will review the current and still evolving genetic advances in the elucidation of the molecular basis of FCD. Activating somatic mutations in the MTOR gene are to date the most frequent mutations found in FCD brain specimens.
Insights
Hyperactivation of the mechanistic target of rapamycin (mTOR) pathway is linked to brain malformations like focal cortical dysplasia (FCD). Activating mutations in the MTOR gene are the most common cause identified in FCD brain samples.
Area of Science:
- Neuroscience
- Genetics
- Developmental Biology
Background:
- The mechanistic target of rapamycin (mTOR) pathway is crucial for cellular functions including growth, proliferation, and metabolism.
- Hyperactivation of the mTOR pathway is increasingly recognized as a key feature in malformations of cortical development (MCD), such as focal cortical dysplasia (FCD) and hemimegalencephaly.
Purpose of the Study:
- To review recent genetic advances in understanding the molecular basis of FCD.
- To elucidate the genetic etiology behind mTOR hyperactivation in FCD.
Main Methods:
- Review of current literature on genetic mutations in FCD.
- Analysis of molecular genetic data from FCD brain specimens.
Main Results:
- Activating somatic mutations in the MTOR gene are the most frequent genetic findings in FCD brain specimens.
- These mutations provide a direct link between genetic alterations and mTOR pathway hyperactivation in FCD.
Conclusions:
- Genetic mutations, particularly in the MTOR gene, are a primary driver of mTOR hyperactivation in FCD.
- Understanding these genetic underpinnings is essential for future research and potential therapeutic strategies for FCD.
More Related Videos
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

